Want to see MTVA full AI Analyst Report?
MTVA Stock Chart & Stats
$1.40
-$0.13(-5.60%)
At close: 4:00 PM EST
$1.40
-$0.13(-5.60%)
Day’s Range― - ―
52-Week Range$0.97 - $19.02
Previous CloseN/A
Volume36.62K
Average Volume (3M)3.42M
Market Cap
$7.49M
Enterprise Value-$9.77M
Total Cash (Recent Filing)$13.73M
Total Debt (Recent Filing)$194.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 18, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding5,164,370
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit651.50
Enterprise Value/Ebitda0.75
Forecast
1Y Price Target
$14.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of DA-1726Robust early clinical weight-loss results (9.1% at Day 54) with favorable safety are a durable fundamental: they validate mechanism, support further development into obesity and MASH indications, improve chances of partner interest, and materially strengthen long-term commercial potential versus undifferentiated entrants.
Pipeline Breadth And Combination StrategyPreclinical synergy for vanoglipel in combination regimens across MASH and T2D creates structural optionality: multiple indication pathways, higher strategic value for partnerships, and diversified clinical risk versus a single-asset company, improving long-term probability of a commercial asset.
Low Financial LeverageVery low debt and minimal leverage preserve financial flexibility for a clinical-stage biotech: it reduces bankruptcy risk, leaves room to raise development capital without servicing heavy interest, and is a durable advantage when converting clinical milestones into partnership or financing options.
Bears Say
Pre-revenue Status And Persistent LossesBeing pre-revenue with sizable recurring net losses is a structural weakness: the company must convert clinical progress to a commercial product or sustained partnerships to ever generate margins, and persistent losses lengthen time to profitability while increasing dilution and execution risk.
High Cash Burn And Negative Operating Cash FlowMaterial, persistent negative operating cash flow forces recurring external funding needs; this constrains strategic choices, can delay programs if capital is scarce, and weakens negotiating leverage with partners or acquirers—a durable constraint until the company reaches self-funding or secures long-term deals.
Limited Cash Runway And Financing RiskA modest cash balance with recent small financing and runway only into late 2026 implies likely near-term fundraising. Repeated raises dilute shareholders, can shift timelines, and may force suboptimal licensing/partnering terms—structural risks for a small developer until larger, durable funding is secured.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.97 and its highest was $19.02 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $7.49M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Aug 18, 2026 which is in 47 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on May 14, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.047.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.82.
How many shares outstanding does MetaVia have?
MetaVia has 5,164,370 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -6.723%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(900.00% Upside)
Technical Analysis
Ownership Overview
3.77% Insiders
0.27% Mutual Funds
0.19% Other Institutional Investors
95.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---